Related Experiment Video
Updated: Jul 4, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer
1Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany. dr.martin.reck@web.de
Abstract:
Chemotherapy has reached a therapeutic plateau in the treatment of advanced non-small cell lung cancer (NSCLC), and effective, better-tolerated treatment strategies are needed. An improved understanding of the molecular processes underlying tumor biology has led to the development of therapies that target these processes. Intracellular signaling pathways related to the vascular endothelial growth factor and the epidermal growth factor receptor both play a central role in tumorigenesis as well as tumor growth, and are therefore rational targets for anti-cancer drug development. Various agents that target these pathways are in clinical development. Some of these have already changed treatment practice in NSCLC, most notably the monoclonal antibody, bevacizumab, in combination with chemotherapy in the first-line setting and the small-molecule tyrosine-kinase inhibitors, erlotinib and gefitinib, in the second-line setting. We will review the clinical data for various novel therapies and identify how these agents are improving outcomes in the first- and second-line treatment of advanced NSCLC.
Insights
Novel targeted therapies show promise for advanced non-small cell lung cancer (NSCLC) treatment, offering improved outcomes and better tolerability beyond traditional chemotherapy. These agents target key tumor growth pathways.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy efficacy in advanced non-small cell lung cancer (NSCLC) has plateaued, necessitating novel treatment strategies.
- Tumorigenesis and growth involve key intracellular signaling pathways, including those regulated by vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
- Targeting these pathways represents a rational approach for developing new anti-cancer drugs.
Purpose of the Study:
- To review clinical data for novel targeted therapies in advanced NSCLC.
- To identify how these agents are improving outcomes in first- and second-line treatment settings.
- To discuss the impact of these therapies on current NSCLC treatment paradigms.
Main Methods:
- Review of clinical trial data for targeted agents in advanced NSCLC.
- Analysis of efficacy and tolerability data for novel therapies.
- Evaluation of treatment outcomes in first- and second-line settings.
Main Results:
- Bevacizumab (monoclonal antibody) combined with chemotherapy has impacted first-line treatment.
- Erlotinib and gefitinib (tyrosine-kinase inhibitors) have become standard in second-line treatment.
- Emerging targeted therapies are demonstrating improved outcomes and better tolerability.
Conclusions:
- Targeted therapies targeting VEGF and EGFR pathways are transforming advanced NSCLC treatment.
- These novel agents offer effective alternatives and improvements over chemotherapy alone.
- Further development and clinical evaluation of these targeted agents are crucial for optimizing patient care.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...